Bicara presents survival data for ficerafusp alfa + Keytruda in head/neck cancer: 21.3 months median OS, 46% 2-year OS rate ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...